PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia

Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic leukemia (B-ALL) and most commonly involve PAX5, encoding the DNA-binding transcription factor paired-box 5. The majority of PAX5 alterations in ALL are heterozygous, a...

Full description

Saved in:
Bibliographic Details
Published in:Blood Vol. 125; no. 23; p. 3609
Main Authors: Dang, Jinjun, Wei, Lei, de Ridder, Jeroen, Su, Xiaoping, Rust, Alistair G, Roberts, Kathryn G, Payne-Turner, Debbie, Cheng, Jinjun, Ma, Jing, Qu, Chunxu, Wu, Gang, Song, Guangchun, Huether, Robert G, Schulman, Brenda, Janke, Laura, Zhang, Jinghui, Downing, James R, van der Weyden, Louise, Adams, David J, Mullighan, Charles G
Format: Journal Article
Language:English
Published: United States 04.06.2015
Subjects:
ISSN:1528-0020, 1528-0020
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic leukemia (B-ALL) and most commonly involve PAX5, encoding the DNA-binding transcription factor paired-box 5. The majority of PAX5 alterations in ALL are heterozygous, and key PAX5 target genes are expressed in leukemic cells, suggesting that PAX5 may be a haploinsufficient tumor suppressor. To examine the role of PAX5 alterations in leukemogenesis, we performed mutagenesis screens of mice heterozygous for a loss-of-function Pax5 allele. Both chemical and retroviral mutagenesis resulted in a significantly increased penetrance and reduced latency of leukemia, with a shift to B-lymphoid lineage. Genomic profiling identified a high frequency of secondary genomic mutations, deletions, and retroviral insertions targeting B-lymphoid development, including Pax5, and additional genes and pathways mutated in ALL, including tumor suppressors, Ras, and Janus kinase-signal transducer and activator of transcription signaling. These results show that in contrast to simple Pax5 haploinsufficiency, multiple sequential alterations targeting lymphoid development are central to leukemogenesis and contribute to the arrest in lymphoid maturation characteristic of ALL. This cross-species analysis also validates the importance of concomitant alterations of multiple cellular growth, signaling, and tumor suppression pathways in the pathogenesis of B-ALL.
AbstractList Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic leukemia (B-ALL) and most commonly involve PAX5, encoding the DNA-binding transcription factor paired-box 5. The majority of PAX5 alterations in ALL are heterozygous, and key PAX5 target genes are expressed in leukemic cells, suggesting that PAX5 may be a haploinsufficient tumor suppressor. To examine the role of PAX5 alterations in leukemogenesis, we performed mutagenesis screens of mice heterozygous for a loss-of-function Pax5 allele. Both chemical and retroviral mutagenesis resulted in a significantly increased penetrance and reduced latency of leukemia, with a shift to B-lymphoid lineage. Genomic profiling identified a high frequency of secondary genomic mutations, deletions, and retroviral insertions targeting B-lymphoid development, including Pax5, and additional genes and pathways mutated in ALL, including tumor suppressors, Ras, and Janus kinase-signal transducer and activator of transcription signaling. These results show that in contrast to simple Pax5 haploinsufficiency, multiple sequential alterations targeting lymphoid development are central to leukemogenesis and contribute to the arrest in lymphoid maturation characteristic of ALL. This cross-species analysis also validates the importance of concomitant alterations of multiple cellular growth, signaling, and tumor suppression pathways in the pathogenesis of B-ALL.
Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic leukemia (B-ALL) and most commonly involve PAX5, encoding the DNA-binding transcription factor paired-box 5. The majority of PAX5 alterations in ALL are heterozygous, and key PAX5 target genes are expressed in leukemic cells, suggesting that PAX5 may be a haploinsufficient tumor suppressor. To examine the role of PAX5 alterations in leukemogenesis, we performed mutagenesis screens of mice heterozygous for a loss-of-function Pax5 allele. Both chemical and retroviral mutagenesis resulted in a significantly increased penetrance and reduced latency of leukemia, with a shift to B-lymphoid lineage. Genomic profiling identified a high frequency of secondary genomic mutations, deletions, and retroviral insertions targeting B-lymphoid development, including Pax5, and additional genes and pathways mutated in ALL, including tumor suppressors, Ras, and Janus kinase-signal transducer and activator of transcription signaling. These results show that in contrast to simple Pax5 haploinsufficiency, multiple sequential alterations targeting lymphoid development are central to leukemogenesis and contribute to the arrest in lymphoid maturation characteristic of ALL. This cross-species analysis also validates the importance of concomitant alterations of multiple cellular growth, signaling, and tumor suppression pathways in the pathogenesis of B-ALL.Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic leukemia (B-ALL) and most commonly involve PAX5, encoding the DNA-binding transcription factor paired-box 5. The majority of PAX5 alterations in ALL are heterozygous, and key PAX5 target genes are expressed in leukemic cells, suggesting that PAX5 may be a haploinsufficient tumor suppressor. To examine the role of PAX5 alterations in leukemogenesis, we performed mutagenesis screens of mice heterozygous for a loss-of-function Pax5 allele. Both chemical and retroviral mutagenesis resulted in a significantly increased penetrance and reduced latency of leukemia, with a shift to B-lymphoid lineage. Genomic profiling identified a high frequency of secondary genomic mutations, deletions, and retroviral insertions targeting B-lymphoid development, including Pax5, and additional genes and pathways mutated in ALL, including tumor suppressors, Ras, and Janus kinase-signal transducer and activator of transcription signaling. These results show that in contrast to simple Pax5 haploinsufficiency, multiple sequential alterations targeting lymphoid development are central to leukemogenesis and contribute to the arrest in lymphoid maturation characteristic of ALL. This cross-species analysis also validates the importance of concomitant alterations of multiple cellular growth, signaling, and tumor suppression pathways in the pathogenesis of B-ALL.
Author Roberts, Kathryn G
Song, Guangchun
Janke, Laura
Downing, James R
Wei, Lei
Cheng, Jinjun
Payne-Turner, Debbie
de Ridder, Jeroen
Schulman, Brenda
Rust, Alistair G
Qu, Chunxu
Zhang, Jinghui
Ma, Jing
Adams, David J
Dang, Jinjun
van der Weyden, Louise
Wu, Gang
Huether, Robert G
Su, Xiaoping
Mullighan, Charles G
Author_xml – sequence: 1
  givenname: Jinjun
  surname: Dang
  fullname: Dang, Jinjun
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 2
  givenname: Lei
  surname: Wei
  fullname: Wei, Lei
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 3
  givenname: Jeroen
  surname: de Ridder
  fullname: de Ridder, Jeroen
  organization: Faculty of Electrical Engineering, Mathematics and Computer Science, Delft Bioinformatics Laboratory, Delft University of Technology, Delft, The Netherlands
– sequence: 4
  givenname: Xiaoping
  surname: Su
  fullname: Su, Xiaoping
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 5
  givenname: Alistair G
  surname: Rust
  fullname: Rust, Alistair G
  organization: Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
– sequence: 6
  givenname: Kathryn G
  surname: Roberts
  fullname: Roberts, Kathryn G
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 7
  givenname: Debbie
  surname: Payne-Turner
  fullname: Payne-Turner, Debbie
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 8
  givenname: Jinjun
  surname: Cheng
  fullname: Cheng, Jinjun
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 9
  givenname: Jing
  surname: Ma
  fullname: Ma, Jing
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 10
  givenname: Chunxu
  surname: Qu
  fullname: Qu, Chunxu
  organization: Department of Computational Biology, St Jude Children's Research Hospital, Memphis, TN; and
– sequence: 11
  givenname: Gang
  surname: Wu
  fullname: Wu, Gang
  organization: Department of Computational Biology, St Jude Children's Research Hospital, Memphis, TN; and
– sequence: 12
  givenname: Guangchun
  surname: Song
  fullname: Song, Guangchun
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 13
  givenname: Robert G
  surname: Huether
  fullname: Huether, Robert G
  organization: Department of Structural Biology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 14
  givenname: Brenda
  surname: Schulman
  fullname: Schulman, Brenda
  organization: Department of Structural Biology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 15
  givenname: Laura
  surname: Janke
  fullname: Janke, Laura
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 16
  givenname: Jinghui
  surname: Zhang
  fullname: Zhang, Jinghui
  organization: Department of Computational Biology, St Jude Children's Research Hospital, Memphis, TN; and
– sequence: 17
  givenname: James R
  surname: Downing
  fullname: Downing, James R
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 18
  givenname: Louise
  surname: van der Weyden
  fullname: van der Weyden, Louise
  organization: Department of Structural Biology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 19
  givenname: David J
  surname: Adams
  fullname: Adams, David J
  organization: Department of Structural Biology, St Jude Children's Research Hospital, Memphis, TN
– sequence: 20
  givenname: Charles G
  orcidid: 0000-0002-1871-1850
  surname: Mullighan
  fullname: Mullighan, Charles G
  organization: Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25855603$$D View this record in MEDLINE/PubMed
BookMark eNpNkE1LxDAYhIOsuB_6D0Ry9FJN3jbZ5LgsfsGCHlS8lTR9q9WkqU1z2H9vwRVkDjOHh2GYJZl1oUNCzjm74lzBdeVCqDNgXGQMMgmSw_qILLgAlTEGbPYvz8kyxk_GeJGDOCFzEEoIyfIFeX3avAnaRmromHwYaEx9P2CMU2w76kOKSH0azTt2GCfOhxpdpKGhxqYRqdv7_iNUzsSxtdRh-kLfmlNy3BgX8ezgK_Jye_O8vc92j3cP280uswL0mJlccom6aJSSFprCNnVuNGqohVJmktZV3ui1yAulKmV1bSRThVRSF6ZSAlbk8re3H8J3wjiWvo0WnTMdTtNLPqEFl8D0hF4c0FR5rMt-aL0Z9uXfF_AD7apkDA
CitedBy_id crossref_primary_10_1038_s41588_018_0315_5
crossref_primary_10_1038_s44321_025_00208_4
crossref_primary_10_1016_j_cancergen_2020_03_001
crossref_primary_10_3390_ijms23147562
crossref_primary_10_1182_blood_2020005756
crossref_primary_10_1016_j_exphem_2015_05_015
crossref_primary_10_1073_pnas_1721678115
crossref_primary_10_1073_pnas_1814397115
crossref_primary_10_1038_s41568_020_00315_z
crossref_primary_10_1155_2017_5326370
crossref_primary_10_1016_j_yexcr_2018_02_010
crossref_primary_10_1038_s41375_019_0430_z
crossref_primary_10_1200_JCO_2016_70_7836
crossref_primary_10_1038_s41375_018_0103_3
crossref_primary_10_1038_s41467_019_13570_y
crossref_primary_10_1182_blood_2020004834
crossref_primary_10_4049_jimmunol_1501277
crossref_primary_10_2903_sp_efsa_2016_EN_955
crossref_primary_10_3390_healthcare9050531
crossref_primary_10_1007_s11684_020_0821_6
crossref_primary_10_3389_fimmu_2023_1285743
crossref_primary_10_3389_fimmu_2021_670280
crossref_primary_10_3389_fonc_2024_1337954
crossref_primary_10_1016_j_beha_2019_101095
crossref_primary_10_1002_gcc_22882
crossref_primary_10_3390_cancers13215511
crossref_primary_10_15252_embj_201695495
crossref_primary_10_1016_S0140_6736_19_33018_1
crossref_primary_10_1182_blood_2018_10_882142
crossref_primary_10_1016_j_ejmg_2015_11_009
crossref_primary_10_3390_ijms21062193
crossref_primary_10_1080_17474086_2020_1685866
crossref_primary_10_1038_ncomms12320
crossref_primary_10_1007_s00428_022_03448_8
crossref_primary_10_3389_fonc_2022_1023606
crossref_primary_10_3389_fimmu_2022_898660
crossref_primary_10_3390_ijms23052755
crossref_primary_10_1038_s41590_018_0234_8
crossref_primary_10_1038_s41598_020_76206_y
crossref_primary_10_1101_gad_349879_122
crossref_primary_10_3390_cancers12123498
crossref_primary_10_1038_s41419_022_05219_4
crossref_primary_10_1016_j_lrr_2016_04_001
crossref_primary_10_1016_j_beha_2020_101193
crossref_primary_10_1177_0300985819852138
crossref_primary_10_1002_gcc_22451
crossref_primary_10_1016_j_blre_2025_101318
crossref_primary_10_1016_j_beha_2017_07_003
crossref_primary_10_1097_CM9_0000000000002018
crossref_primary_10_1093_carcin_bgac034
crossref_primary_10_1097_HS9_0000000000000043
crossref_primary_10_1016_j_exphem_2016_11_002
crossref_primary_10_1038_s41590_024_01995_7
crossref_primary_10_1182_blood_2018852400
crossref_primary_10_1016_j_jmb_2016_04_004
crossref_primary_10_1016_j_exphem_2016_04_011
crossref_primary_10_1016_j_ejmg_2023_104725
ContentType Journal Article
Copyright 2015 by The American Society of Hematology.
Copyright_xml – notice: 2015 by The American Society of Hematology.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1182/blood-2015-02-626127
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
ExternalDocumentID 25855603
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Cancer Research UK
  grantid: 13031
– fundername: NCI NIH HHS
  grantid: P30 CA021765
– fundername: Wellcome Trust
– fundername: NCI NIH HHS
  grantid: P30 CA016056
GroupedDBID ---
-~X
.55
0R~
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6J9
AAEDW
AALRI
AAXUO
ABOCM
ACGFO
ACVFH
ADBBV
ADCNI
ADVLN
AENEX
AEUPX
AFOSN
AFPUW
AGCQF
AIGII
AITUG
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EFKBS
EIF
EJD
EX3
F5P
FDB
FRP
GS5
GX1
H13
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
NPM
OK1
P2P
R.V
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
7X8
ID FETCH-LOGICAL-c529t-a3616e94f886c2f4cfd3a9e92d588a8a899b3f9753488b8c9da608468694ab852
IEDL.DBID 7X8
ISICitedReferencesCount 63
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000357281200016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1528-0020
IngestDate Mon Sep 29 03:48:36 EDT 2025
Mon Jul 21 05:57:17 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 23
Language English
License 2015 by The American Society of Hematology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c529t-a3616e94f886c2f4cfd3a9e92d588a8a899b3f9753488b8c9da608468694ab852
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-1871-1850
OpenAccessLink https://ashpublications.org/blood/article-pdf/125/23/3609/1388114/3609.pdf
PMID 25855603
PQID 1686416209
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1686416209
pubmed_primary_25855603
PublicationCentury 2000
PublicationDate 2015-Jun-04
20150604
PublicationDateYYYYMMDD 2015-06-04
PublicationDate_xml – month: 06
  year: 2015
  text: 2015-Jun-04
  day: 04
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Blood
PublicationTitleAlternate Blood
PublicationYear 2015
SSID ssj0014325
Score 2.440747
Snippet Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic leukemia (B-ALL) and most...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 3609
SubjectTerms Animals
Gene Deletion
Mice
Mice, Mutant Strains
Neoplasms, Experimental - genetics
Neoplasms, Experimental - metabolism
Neoplasms, Experimental - pathology
PAX5 Transcription Factor - genetics
PAX5 Transcription Factor - metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Title PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia
URI https://www.ncbi.nlm.nih.gov/pubmed/25855603
https://www.proquest.com/docview/1686416209
Volume 125
WOSCitedRecordID wos000357281200016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFH6o43ZxGbdxI4J4C3ZJM8lJRnHwoMMcdJjbkKYpDDrtaFvBf-9L2sGTIEihzaFLlteXL2_JB3Cp_CD2eMwpVyyirMsVlZon1AjjW6-ZTF0e9-ixOxiI8VgOG4Nb0YRVLnSiU9RJrq2N_NrngiN4CDx5M3-nljXKelcbCo1laIUIZaxUd8c_XgQWOtJVnKIEtbioSZ1DSH1dh4Xj7Ofyk7ndSKv7O8h0k01_-7_V3IGtBmaSXi0Xu7Bksjbs9TJcYs--yBVxgZ_Oot6GtdtFaeNuQf_WhvWnxuu-B6NhbxyRaUEUKatZ_kGKau7iZ7E4zYg1Hhgyq0pUTag48T5Hr1OQPCVKV6Uhb18oM3mMQB2rQ95M9YqfUfvw0r9_vnugDR8D1VEgS6pC7nMjWSoE10HKdJqEShoZJJEQCg8p4zC1mbqoFWKhZaK4h_hGcMlULKLgAFayPDNHQDTqYJZyGfiaIWSMlIdvi4Ul_sCL0B24WHTvBNttnRgqM9icyU8Hd-CwHqPJvN6YYxLg2gcRXHj8h6dPYLMefU49dgqtFP92cwar-rOcFh_nTpDwPBg-fQO-8tDg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PAX5+is+a+tumor+suppressor+in+mouse+mutagenesis+models+of+acute+lymphoblastic+leukemia&rft.jtitle=Blood&rft.au=Dang%2C+Jinjun&rft.au=Wei%2C+Lei&rft.au=de+Ridder%2C+Jeroen&rft.au=Su%2C+Xiaoping&rft.date=2015-06-04&rft.eissn=1528-0020&rft.volume=125&rft.issue=23&rft.spage=3609&rft_id=info:doi/10.1182%2Fblood-2015-02-626127&rft_id=info%3Apmid%2F25855603&rft_id=info%3Apmid%2F25855603&rft.externalDocID=25855603
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon